Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Medtronic Bakken Research Center
Information provided by (Responsible Party):
Medtronic Vascular
ClinicalTrials.gov Identifier:
NCT00476957
First received: May 21, 2007
Last updated: May 27, 2014
Last verified: May 2014
Results First Received: September 17, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Health Services Research
Condition: Ischemic Heart Disease
Intervention: Device: Stent

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
8709 patients were randomized from May 2007 until December 2008 in 196 participating hospitals in 36 countries across five continents.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
80 patients were excluded because there was no validly signed consent available during monitoring and 2 patients retracted their consent before the procedure, resulting in a total of 8709 patients randomised.

Reporting Groups
  Description
E-ZES

Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System

Stent : Stent implantation

C-SES

Cordis Cypher® Sirolimus-eluting Coronary Stent

Stent : Stent implantation


Participant Flow:   Overall Study
    E-ZES     C-SES  
STARTED     4357     4352  
COMPLETED     4181     4159  
NOT COMPLETED     176     193  
Lost to Follow-up                 176                 193  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intention to treat analysis has been used.

Reporting Groups
  Description
E-ZES

Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System

Stent : Stent implantation

C-SES

Cordis Cypher® Sirolimus-eluting Coronary Stent

Stent : Stent implantation

Total Total of all reporting groups

Baseline Measures
    E-ZES     C-SES     Total  
Number of Participants  
[units: participants]
  4357     4352     8709  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     2428     2468     4896  
>=65 years     1929     1884     3813  
Age  
[units: years]
Mean ± Standard Deviation
  62.3  ± 10.6     62.1  ± 10.7     62.2  ± 10.6  
Gender  
[units: participants]
     
Female     1017     1044     2061  
Male     3340     3308     6648  
Region of Enrollment  
[units: participants]
     
Europe     3180     3179     6359  
South Asia     623     622     1245  
North America     115     115     230  
South America     25     25     50  
Australia     207     207     414  
New Zealand     43     42     85  
Middle East     164     162     326  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation   [ Time Frame: 3 years ]

2.  Secondary:   Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions   [ Time Frame: 3 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information